From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development
This monograph reviews the discovery and development of the cyclin-dependent kinase inhibitor roscovitine (R-roscovitine, CYC202, Seliciclib). The authors summarise the in vitro and in vivo data that have formed the basis for clinical investigation of Seliciclib as an anti-cancer drug. Kinase selec...
Main Authors: | Nikolai Zhelev, Dimitar Trifonov, Shudong Wang, Moustapha Hassan, Ibrahim El Serafi |
---|---|
Format: | Article |
Language: | English |
Published: |
Pensoft Publishers
2013-12-01
|
Series: | BioDiscovery |
Subjects: | |
Online Access: | https://biodiscovery.pensoft.net/article/8956/download/pdf/ |
Similar Items
-
Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with <i>Pseudomonas aeruginosa</i>: A Study on Population Pharmacokinetics with Monte Carlo Simulations
by: Cyril Leven, et al.
Published: (2020-11-01) -
Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin Receptor Overexpressed Cancer Cells
by: Guan Zhen He, et al.
Published: (2021-03-01) -
Effects of Roscovitine on In Vitro Development of Porcine Oocyte Using Brilliant Cresyl Blue
by: Pantu Kumar Roy, et al.
Published: (2017-09-01) -
CyanoCyc cyanobacterial web portal
by: Lisa R. Moore, et al.
Published: (2024-01-01) -
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells
by: Lucas Le Roy, et al.
Published: (2021-01-01)